MedTrace Logo

A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

NCT01222403 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 767

Last updated 2019-06-12

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety of an influenza (flu) vaccine in Korean men and women aged 65 years and older.

Conditions

Interventions

BIOLOGICAL

Fluad_MF59-adjuvanted trivalent influenza subunit vaccine

BIOLOGICAL

Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222403 on ClinicalTrials.gov